JP2005514941A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005514941A5 JP2005514941A5 JP2003562139A JP2003562139A JP2005514941A5 JP 2005514941 A5 JP2005514941 A5 JP 2005514941A5 JP 2003562139 A JP2003562139 A JP 2003562139A JP 2003562139 A JP2003562139 A JP 2003562139A JP 2005514941 A5 JP2005514941 A5 JP 2005514941A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- heat shock
- mammalian
- binding
- shock protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101150013553 CD40 gene Proteins 0.000 claims 44
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 44
- 239000012634 fragment Substances 0.000 claims 32
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims 31
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims 31
- 239000000427 antigen Substances 0.000 claims 22
- 102000036639 antigens Human genes 0.000 claims 22
- 108091007433 antigens Proteins 0.000 claims 22
- 230000002163 immunogen Effects 0.000 claims 11
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 claims 4
- 101150031823 HSP70 gene Proteins 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 101150052825 dnaK gene Proteins 0.000 claims 4
- 230000001965 increasing effect Effects 0.000 claims 4
- 210000004962 mammalian cell Anatomy 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- -1 IL-1α Proteins 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 102100032937 CD40 ligand Human genes 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 101000884675 Coxiella burnetii (strain RSA 493 / Nine Mile phase I) Co-chaperonin GroES Proteins 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 239000003710 calcium ionophore Substances 0.000 claims 1
- 230000004700 cellular uptake Effects 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34257001P | 2001-12-26 | 2001-12-26 | |
| US34388401P | 2001-12-27 | 2001-12-27 | |
| US37262002P | 2002-04-12 | 2002-04-12 | |
| US39934202P | 2002-07-29 | 2002-07-29 | |
| US41483402P | 2002-09-28 | 2002-09-28 | |
| PCT/US2002/041373 WO2003062262A2 (en) | 2001-12-26 | 2002-12-24 | Modulation of heat-shock-protein-based immunotherapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005514941A JP2005514941A (ja) | 2005-05-26 |
| JP2005514941A5 true JP2005514941A5 (enExample) | 2006-02-23 |
Family
ID=27617918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003562139A Pending JP2005514941A (ja) | 2001-12-26 | 2002-12-24 | 熱ショックタンパク質に基づく免疫治療の調節 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20040071656A1 (enExample) |
| EP (1) | EP1501860A4 (enExample) |
| JP (1) | JP2005514941A (enExample) |
| IL (1) | IL162747A0 (enExample) |
| WO (1) | WO2003062262A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7420037B2 (en) * | 2003-02-13 | 2008-09-02 | Antigenics Inc. | Heat shock protein-based vaccines and immunotherapies |
| US7309491B2 (en) * | 2003-04-11 | 2007-12-18 | Antigenics Inc. | Heat shock protein-based vaccines and immunotherapies |
| JP2007525448A (ja) * | 2003-04-11 | 2007-09-06 | アンティジェニクス インコーポレーテッド | 改良された熱ショックタンパク質に基づくワクチンおよび免疫治療 |
| CA2549167A1 (en) * | 2003-12-11 | 2005-06-30 | Schering Corporation | Inhibitors of hepatitis c virus ns3/ns4a serine protease |
| US7575738B2 (en) * | 2004-08-13 | 2009-08-18 | General Electric Company | Heat shock protein as a targeting agent for endothelium-specific in vivo transduction |
| CN103687616A (zh) * | 2011-07-21 | 2014-03-26 | 生物技术工具公司 | Dnak制剂 |
| WO2013156493A1 (en) * | 2012-04-16 | 2013-10-24 | Lipotec S.A. | Compounds for the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions |
| IL293135A (en) * | 2015-05-13 | 2022-07-01 | Agenus Inc | Composition comprising at least two different complexes of a purified stress protein bound to an antigenic peptide |
| AU2018314269B2 (en) * | 2017-08-11 | 2022-12-08 | University Of Kentucky Research Foundation | Anti-neurodegenerative therapeutic, method of manufacture, and use |
| JP2021522239A (ja) | 2018-04-26 | 2021-08-30 | アジェナス インコーポレイテッド | 熱ショックタンパク質結合ペプチド組成物およびその使用方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5750119A (en) * | 1994-01-13 | 1998-05-12 | Mount Sinai School Of Medicine Of The City University Of New York | Immunotherapeutic stress protein-peptide complexes against cancer |
| EP1067194A1 (en) * | 1999-04-16 | 2001-01-10 | F. Hoffmann-La Roche Ag | Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof |
| US20020086276A1 (en) * | 2000-12-28 | 2002-07-04 | Srivastava Pramod K. | Immunotherapeutic methods for extracorporeal modulation of CD36 and its ligands |
-
2002
- 2002-12-23 US US10/328,953 patent/US20040071656A1/en not_active Abandoned
- 2002-12-24 JP JP2003562139A patent/JP2005514941A/ja active Pending
- 2002-12-24 IL IL16274702A patent/IL162747A0/xx unknown
- 2002-12-24 EP EP02806627A patent/EP1501860A4/en not_active Withdrawn
- 2002-12-24 WO PCT/US2002/041373 patent/WO2003062262A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Koffler et al. | Variable patterns of immunoglobulin and complement deposition in the kidneys of patients with systemic lupus erythematosus | |
| Wang et al. | Selective degradation of PD‐L1 in cancer cells by enzyme‐instructed self‐assembly | |
| Edelman | Antibody structure and molecular immunology | |
| Wang et al. | Site-specific UBITh® amyloid-β vaccine for immunotherapy of Alzheimer's disease | |
| US9205144B2 (en) | Identification of conserved peptide blocks in homologous polypeptides | |
| JP2004532817A5 (enExample) | ||
| BR9917218A (pt) | Anticorpos monoclonais, antìgenos, e diagnósticoe terapia de doenças malignas | |
| JP2005514941A5 (enExample) | ||
| JPH03505590A (ja) | ユビキチン及びｈ２ａヒストンの結合体から成る合成ペプチド | |
| BRPI0511751A (pt) | usos médicos de conjugados veìculos de peptìdeos de tnf não-humano | |
| Ménoret et al. | Purification of multiple heat shock proteins from a single tumor sample | |
| WO2000025722A3 (en) | ENHANCED VACCINES COMPRISING SELF AND NON-SELF IgE PORTIONS OR DIMERIC ANTIGENS | |
| Kalluri | Goodpasture syndrome | |
| Moyle et al. | A circular antibody-antigen complex is responsible for increased affinity shown by mixtures of monoclonal antibodies to human chorionic gonadotropin. | |
| Qian et al. | Immunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface protein-1 | |
| Biswas et al. | The N-terminal fragment of GRP94 is sufficient for peptide presentation via professional antigen-presenting cells | |
| Arimilli et al. | Refolding and Reconstitution of Functionally Active Complexes of Human Leukocyte Antigen DR2 and Myelin Basic Protein Peptide from Recombinant α and β Polypeptide Chains (∗) | |
| JP2024036461A (ja) | 自己集合ペプチド骨格 | |
| Li | In vitro reconstitution of heat shock protein–peptide complexes for generating peptide-specific vaccines against cancers and infectious diseases | |
| CN105504015A (zh) | 一种mhc-i类限制性抗肿瘤ctl表位肽 | |
| Ma et al. | Design and synthesis of HLA-A* 02-restricted Hantaan virus multiple-antigenic peptide for CD8+ T cells | |
| JP2005522209A5 (enExample) | ||
| Whitaker et al. | Antigenic regions for the humoral response to myelin basic protein | |
| Zhang et al. | A mimotope of pre-S2 region of surface antigen of viral hepatitis B screened by phage display | |
| Sharif et al. | In silico design of CT26 polytope and its surface display by ClearColi™-derived outer membrane vesicles as a cancer vaccine candidate against colon carcinoma |